New Diagnostic Methods And Treatments Needed To Fight Against Alzheimer's Disease

The test and aesculapian curen of Alzheimer's disease, a information that according to starring researchers successful nan section should beryllium treated, has now precocious significantly. A bid of articles successful The Lancet provides some a broad and thorough reappraisal of existent research.

This is simply a clear statement, and a wake-up telephone for Sweden. We person reached a shape wherever Alzheimer's illness is nary longer thing you tin do small about. We must now instrumentality nan caller diagnostic methods and nan caller medicines, and alteration nan healthcare system.”

Henrik Zetterberg, professor of neurochemistry, University of Gothenburg

The articles published early Tuesday represent of “The Lancet Series connected Alzheimer's disease" and summarize nan existent authorities of Alzheimer's investigation worldwide. Henrik Zetterberg is co-author of 2 of nan 3 articles.

Strong world consensus

The bid describes nan history of research, nan awesome discoveries, controversies on nan way, and nan existent statement among nan mostly of scientists successful nan world that nan pathology of nan disease, pinch precocious levels of amyloid and tau proteins successful nan brain, is initiating nan condition.

Similarly, location is simply a statement that group undergoing representation assessments should beryllium offered a digit prick truthful that their humor tin beryllium analyzed for biomarkers of Alzheimer's disease, preferably astatine an early shape erstwhile representation and intelligence abilities still only uncover mild symptoms.

“The statement is whether nan caller objective tests are adequate, and whether nan caller medicines person a clinically meaningful effect. The reply to these questions is yes, nan tests are adequate, and nan medicines are useful and should beryllium used, arsenic agelong arsenic nan consequence of broadside effects, specified arsenic cardiovascular disease, is decently managed,” says Henrik Zetterberg.

More and much tests successful Sweden

The EU has approved nan medicinal products lecanemab and donanemab, which slow nan progression of mild dementia successful Alzheimer's illness by removing amyloid plaques successful nan brain. Since nan approval, different countries successful nan EU person progressed to different degrees. Swedish healthcare is waiting for regulatory support earlier nan medicines tin commencement being used.

Meanwhile, much and much humor samples for Alzheimer's testing are being taken during basal representation assessments successful Swedish superior care, arsenic a complement to cognitive tests and assessments of beingness and intelligence health, including interventions to norm out, for example, stress, slump aliases encephalon tumor.

In Henrik Zetterberg's investigation and laboratory situation astatine Sahlgrenska University Hospital Mölndal, nan influx of Alzheimer's humor tests for study has accrued successful number successful caller months alone:

“Every week we tally possibly 40-50 samples, chiefly from Sweden and from different parts of nan country, and I expect that to summation importantly this fall,” he says.

This does not interest screening, Zetterberg emphasizes, but regular attraction for patients who activity thief because they consciousness that their representation and intelligence abilities are failing. One of his Lancet articles describes nan improvement wrong Alzheimer's diagnosis arsenic a revolution.

“It is awesome that we person it implemented successful Sweden; we are astatine nan objective cutting edge. The truth that we do not yet person nan medicines disposable is annoying and ethically problematic to opportunity nan least. The Lancet articles return a stand, stating that we now person thing that really looks good, and we tin put nan chat astir nan benefits down us,” concludes Henrik Zetterberg.